12/3
07:02 pm
dcth
Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]
Medium
Report
Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]
12/3
04:01 pm
dcth
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Low
Report
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
12/2
03:41 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:05 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
04:30 pm
dcth
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]
Medium
Report
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]
11/20
04:01 pm
dcth
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Medium
Report
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
11/20
01:34 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:36 am
dcth
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma [Yahoo! Finance]
Low
Report
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma [Yahoo! Finance]
11/18
08:00 am
dcth
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Low
Report
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
11/18
05:22 am
dcth
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT [Yahoo! Finance]
Low
Report
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT [Yahoo! Finance]
11/14
04:01 pm
dcth
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
08:41 am
dcth
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients [Yahoo! Finance]
Medium
Report
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients [Yahoo! Finance]
11/13
08:30 am
dcth
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Medium
Report
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
11/9
01:11 am
dcth
Delcath Systems (NASDAQ:DCTH) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Delcath Systems (NASDAQ:DCTH) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
11/6
04:28 pm
dcth
Delcath Systems to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Neutral
Report
Delcath Systems to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/6
04:01 pm
dcth
Delcath Systems to Participate in Upcoming Investor Conferences
Neutral
Report
Delcath Systems to Participate in Upcoming Investor Conferences
11/5
10:07 am
dcth
Delcath Systems (NASDAQ:DCTH) had its price target lowered by analysts at Stephens from $25.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its price target lowered by analysts at Stephens from $25.00 to $18.00. They now have an "overweight" rating on the stock.
11/4
05:38 pm
dcth
Should Delcath Systems' Transition to Year-to-Date Profitability Prompt a Rethink for DCTH Investors? [Yahoo! Finance]
Medium
Report
Should Delcath Systems' Transition to Year-to-Date Profitability Prompt a Rethink for DCTH Investors? [Yahoo! Finance]
11/4
05:19 pm
dcth
Delcath outlines 40 active center target and 150% HEPZATO treatment volume growth for 2025 amid CHOPIN data momentum [Seeking Alpha]
Medium
Report
Delcath outlines 40 active center target and 150% HEPZATO treatment volume growth for 2025 amid CHOPIN data momentum [Seeking Alpha]
11/4
12:38 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $23.00 price target on the stock.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $23.00 price target on the stock.
11/4
08:00 am
dcth
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
Medium
Report
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
10/21
08:12 pm
dcth
Is Stronger Guidance and CHOPIN Data Changing the Investment Case for Delcath Systems (DCTH)? [Yahoo! Finance]
Medium
Report
Is Stronger Guidance and CHOPIN Data Changing the Investment Case for Delcath Systems (DCTH)? [Yahoo! Finance]
10/21
12:29 pm
dcth
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $21.00 price target on the stock.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $21.00 price target on the stock.
10/21
10:59 am
dcth
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at Craig Hallum.
Low
Report
Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at Craig Hallum.
10/21
08:30 am
dcth
Delcath Systems to Host Third Quarter 2025 Earnings Call
Low
Report
Delcath Systems to Host Third Quarter 2025 Earnings Call